These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 37528088)

  • 21. Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis.
    Noori M; Yazdanpanah N; Rezaei N
    Cancer Cell Int; 2023 Sep; 23(1):193. PubMed ID: 37670301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
    Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.
    Athni TS; Barmettler S
    Ann Allergy Asthma Immunol; 2023 Jun; 130(6):699-712. PubMed ID: 36706910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
    Landgren O; Nadeem O
    Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011.
    Menkis AH; Martin J; Cheng DC; Fitzgerald DC; Freedman JJ; Gao C; Koster A; Mackenzie GS; Murphy GJ; Spiess B; Ad N
    Innovations (Phila); 2012; 7(4):229-41. PubMed ID: 23123988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.
    Balmaceda N; Aziz M; Chandrasekar VT; McClune B; Kambhampati S; Shune L; Abdallah AO; Anwer F; Majeed A; Qazilbash M; Ganguly S; McGuirk J; Mohyuddin GR
    BMC Cancer; 2021 Jun; 21(1):730. PubMed ID: 34172037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies.
    Swan D; Routledge D; Harrison S
    Br J Haematol; 2022 Feb; 196(3):488-506. PubMed ID: 34472091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
    Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
    Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.
    Sarmati L; Andreoni M; Antonelli G; Arcese W; Bruno R; Coppola N; Gaeta GB; Galli M; Girmenia C; Mikulska M; Pane F; Perno CF; Picardi M; Puoti M; Rambaldi A; Svicher V; Taliani G; Gentile G
    Clin Microbiol Infect; 2017 Dec; 23(12):935-940. PubMed ID: 28668466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma.
    Giralt S; Jolles S; Kerre T; Lazarus HM; Mustafa SS; Papanicolaou GA; Ria R; Vinh DC; Wingard JR
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):719-732. PubMed ID: 37353432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.
    Reynolds G; Cliff ERS; Mohyuddin GR; Popat R; Midha S; Liet Hing MN; Harrison SJ; Kesselheim AS; Teh BW
    Blood Adv; 2023 Oct; 7(19):5898-5903. PubMed ID: 37467036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel.
    Girmenia C; Cavo M; Corso A; Di Raimondo F; Musto P; Offidani M; Petrucci MT; Rosato A; Barosi G
    Crit Rev Oncol Hematol; 2022 Apr; 172():103623. PubMed ID: 35151867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of infection associated with new therapies for lymphoproliferative syndromes.
    Los-Arcos I; Aguilar-Company J; Ruiz-Camps I
    Med Clin (Barc); 2020 Feb; 154(3):101-107. PubMed ID: 31771856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis.
    Nejadghaderi SA; Balibegloo M; Noori M; Fayyaz F; Saghazadeh A; Rezaei N
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):307-318. PubMed ID: 36856069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is the optimal antimicrobial prophylaxis to prevent postoperative infectious complications after liver transplantation? A systematic review of the literature and expert panel recommendations.
    Campos-Varela I; Blumberg EA; Giorgio P; Kotton CN; Saliba F; Wey EQ; Spiro M; Raptis DA; Villamil F;
    Clin Transplant; 2022 Oct; 36(10):e14631. PubMed ID: 35257411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of infection associated with targeted therapies for solid organ and hematological malignancies.
    Ruiz-Camps I; Aguilar-Company J
    Ther Adv Infect Dis; 2021; 8():2049936121989548. PubMed ID: 33680453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colony-stimulating factors for the management of neutropenia in cancer patients.
    Dale DC
    Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization.
    Teh BW; Slavin MA; Harrison SJ; Worth LJ
    Expert Rev Anti Infect Ther; 2015; 13(11):1325-36. PubMed ID: 26489539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.